Express Scripts settlement with FTC includes changes to insulin pricing practices and reshoring of rebate aggregator.
• Express Scripts settles with FTC over insulin pricing.
• Changes include reshoring rebate aggregator and formulary adjustments.
• Settlement impacts Cigna’s pharmacy benefit management practices.
Settlement Details
Express Scripts, a pharmacy benefit manager under Cigna, has reached a settlement with the Federal Trade Commission (FTC) regarding its insulin pricing practices. The agreement, announced on 10 September 2025, mandates significant changes to the company’s business operations. These changes include no longer prioritizing expensive drugs over cheaper alternatives on standard formularies and reshoring its controversial rebate aggregator. This settlement aims to address concerns about the affordability and accessibility of insulin for patients.
The settlement is considered a landmark decision in the ongoing scrutiny of pharmacy benefit managers and their role in drug pricing. The FTC’s involvement underscores the regulatory focus on ensuring fair pricing practices in the pharmaceutical industry. The reshoring of the rebate aggregator is expected to increase transparency and potentially lower costs for consumers.
Impact on Cigna’s Operations
Cigna’s pharmacy benefit management (PBM) division, Express Scripts, will undergo significant operational changes as a result of this settlement. The company will need to adjust its formulary practices to ensure that more affordable drug options are prioritized. This move is expected to benefit patients by providing access to cost-effective medications, particularly for those requiring insulin.
The reshoring of the rebate aggregator is a critical component of the settlement. By bringing this function back in-house, Express Scripts aims to enhance transparency in its pricing strategies. This change is anticipated to improve trust among stakeholders and align with regulatory expectations.
Market Implications
The settlement between Express Scripts and the FTC has broader implications for the pharmaceutical market. It highlights the increasing regulatory scrutiny on PBMs and their influence on drug pricing. As a result, other PBMs may face similar pressures to revise their business practices to align with regulatory standards.
Analysts predict that this settlement could lead to a shift in how PBMs operate, potentially resulting in more competitive pricing for medications. The focus on transparency and affordability is likely to resonate with consumers and policymakers alike, driving further changes in the industry.
For more updates on Market Access, visit our Market Access section.